Jpmorgan Chase & CO Fate Therapeutics Inc Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,669,562 shares of FATE stock, worth $2.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,669,562
Previous 1,837,304 9.13%
Holding current value
$2.37 Million
Previous $6.43 Million 57.17%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$1.61 - $3.35 $270,064 - $561,935
-167,742 Reduced 9.13%
1,669,562 $2.75 Million
Q3 2024

Dec 26, 2024
BUY
$3.12 - $5.57 $883,209 - $1.58 Million
283,080 Added 18.21%
1,837,304 $6.43 Million
Q3 2024

Nov 08, 2024
BUY
$3.12 - $5.57 $883,209 - $1.58 Million
283,080 Added 18.21%
1,837,304 $6.43 Million
Q2 2024

Dec 26, 2024
SELL
$3.26 - $7.08 $922,840 - $2 Million
-283,080 Reduced 15.41%
1,554,224 $5.1 Million
Q2 2024

Aug 12, 2024
SELL
$3.26 - $7.08 $668,616 - $1.45 Million
-205,097 Reduced 11.66%
1,554,224 $5.1 Million
Q1 2024

Dec 26, 2024
SELL
$3.54 - $8.35 $276,059 - $651,158
-77,983 Reduced 4.24%
1,759,321 $12.9 Million
Q1 2024

May 10, 2024
SELL
$3.54 - $8.35 $1.11 Million - $2.62 Million
-313,185 Reduced 15.11%
1,759,321 $12.9 Million
Q4 2023

Dec 26, 2024
BUY
$1.65 - $3.94 $388,083 - $926,695
235,202 Added 12.8%
2,072,506 $7.75 Million
Q4 2023

Feb 12, 2024
SELL
$1.65 - $3.94 $862,402 - $2.06 Million
-522,668 Reduced 20.14%
2,072,506 $7.75 Million
Q3 2023

Nov 14, 2023
SELL
$2.02 - $5.04 $269,607 - $672,683
-133,469 Reduced 4.89%
2,595,174 $5.5 Million
Q2 2023

Aug 11, 2023
BUY
$4.76 - $6.59 $4.77 Million - $6.61 Million
1,002,914 Added 58.12%
2,728,643 $13 Million
Q1 2023

May 18, 2023
BUY
$4.24 - $11.12 $465,764 - $1.22 Million
109,850 Added 6.8%
1,725,729 $9.84 Million
Q1 2023

May 11, 2023
BUY
$4.24 - $11.12 $631,230 - $1.66 Million
148,875 Added 10.15%
1,615,879 $9.21 Million
Q4 2022

Feb 13, 2023
SELL
$9.86 - $23.83 $5.58 Million - $13.5 Million
-566,199 Reduced 27.85%
1,467,004 $14.8 Million
Q3 2022

Nov 14, 2022
BUY
$21.04 - $36.06 $753,147 - $1.29 Million
35,796 Added 1.79%
2,033,203 $45.6 Million
Q2 2022

Aug 11, 2022
BUY
$17.78 - $42.39 $2.41 Million - $5.75 Million
135,701 Added 7.29%
1,997,407 $49.5 Million
Q1 2022

May 11, 2022
SELL
$29.67 - $60.28 $2.1 Million - $4.27 Million
-70,758 Reduced 3.66%
1,861,706 $72.2 Million
Q4 2021

Feb 10, 2022
BUY
$47.84 - $64.34 $11 Million - $14.8 Million
229,849 Added 13.5%
1,932,464 $113 Million
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $101 Million - $163 Million
1,702,615 New
1,702,615 $101 Million

Others Institutions Holding FATE

# of Institutions
167
Shares Held
101M
Call Options Held
41.3K
Put Options Held
15.9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $138M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email